Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

OBJECTIVE: This study was to investigate the efficacy and safety of gefitinib plus anlotinib for patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line setting. METHODS: A total of 36 patients with previously-untreated EGFR positive advanced NSCLC were included in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wen-Xia, Peng, Jing-Cui, Wang, Yun, Jin, Hao, Geng, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059207/
https://www.ncbi.nlm.nih.gov/pubmed/35509604
http://dx.doi.org/10.2147/IJGM.S350771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059207/
https://www.ncbi.nlm.nih.gov/pubmed/35509604
http://dx.doi.org/10.2147/IJGM.S350771

Ejemplares similares